CLINICAL_TRIALS trial_result · 2018-02-07

Clinical Trial Update: Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012) [Phase 2]

Phase 2 trial evaluating MK-7622 as adjunct therapy in Alzheimer's disease was terminated with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Merck Sharp & Dohme LLC | Conditions: Alzheimer's Disease | Phase 2 | Status: TERMINATED | Results posted: 2018-02-07